$599

Novo Partners for Q3M AOMs; Clywedog Announces Ph1b T2DM Data

Two cardiometabolic-related news items have been observed: Novo partnered with Nanexa to develop up to five ultra-long-acting obesity/T2DM assets (view press release), and Clywedog Therapeutics announced Ph1b data for its menin inhibitor in T2DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here